Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
Additional Reading: Sikiric P, Seiwerth S, Romic Z, et al
Through hormone optimization, nutrient therapy, and lifestyle changes, we help clear the mental haze, restoring mental clarity, focus, and cognitive performance, so you can feel sharp and alert again
Tirzepatide: a medicine to manage type 2 diabetes and weight
See-July 3, 2024 Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide- Jimena Tatiana Hathaway, MD, MPH
Cholelithiasis (gallstones) was reported at low rates in the Phase 2 trial Incidence was slightly higher in higher-dose groups, though absolute numbers were small This observation is not unique to retatrutide semaglutide and tirzepatide trials also reported gallbladder events Cardiovascular Observations Heart rate changes were documented in clinical trial participants: Small mean increases in heart rate (2-4 bpm) were observed in active treatment groups This is consistent with GLP-1 agonist class effects semaglutide and tirzepatide produce similar heart rate increases No increased rate of major adverse cardiovascular events (MACE) was observed in Phase 2 TRIUMPH-4 is specifically designed to evaluate cardiovascular outcomes at scale Injection Site Reactions As a subcutaneous injectable, injection site reactions were reported: Injection site erythema, pain, and pruritus were documented at low rates Most injection site events were Grade 1 (mild) No injection site reactions led to treatment discontinuation in published data How Retatrutide Adverse Events Compare to Other GLP-1 Compounds Comparing adverse event profiles across different trials has significant limitations patient populations, dose ranges, and endpoint definitions vary
